Cytogen Cuts 75 Percent of AxCell Biosciences’ Staff
AxCell Biosciences said last week it had laid off three out of four employees and suspended “certain projects” as its parent, Cytogen, tries to cut costs and focus more on its core R&D. Cytogen said AxCell will continue to develop its signal-transduction pathway database for clinical research and functional proteomics.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
